Clinical Trial: A Phase II Study of Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369791) titled 'A Phase II Study of Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.' on Jan. 19.

Brief Summary: A Randomized Phase II Study. To assess the difference in objective response rate (ORR) between adult patients with advanced biliary tract cancer assigned to nivolumab plus relatlimab 360 mg/360 mg in combination with GC or nivolumab plus GC as first-line treatment.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Biliary Tract Cancer(BTC)

Intervention: DRUG: Nivolumab

Specified dose on specified days

DRUG: Gemcitabine

Specified dose on specifi...